Telix Pharmaceuticals (ASX:TLX) has announced that the US FDA has accepted its Biologics License Application for its breakthrough investigational kidney cancer PET imaging agent TLX250-CDx (Zircaix, 89ZrDFO-girentuximab). …
US FDA accepts application for Telix's Zircaix and grants priority review
February 26, 2025 Australian Biotech
Latest Video
New Stories
-
Rare Cancers welcomes future funding for 'game-changing' cancer service
February 27, 2025 - - Latest News -
US biotech industry welcomes proposed change to price negotiation power
February 27, 2025 - - Latest News -
HTA go-slow on newborn screening leaves parents waiting and waiting
February 27, 2025 - - Latest News -
Officials blame companies for not highlighting quality of life benefits
February 26, 2025 - - Latest News -
US FDA accepts application for Telix's Zircaix and grants priority review
February 26, 2025 - - Australian Biotech -
Arovella receives commitments for $15 million following cancellation of January placement
February 26, 2025 - - Australian Biotech -
MTPConnect refreshes board with new appointment and retirement
February 26, 2025 -